Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
2.62 USD | +5.22% | -10.88% | -31.77% |
Financials (USD)
Sales 2024 * | - | Sales 2025 * | - | Capitalization | 157M |
---|---|---|---|---|---|
Net income 2024 * | -69M | Net income 2025 * | -91M | EV / Sales 2024 * | - |
Net cash position 2024 * | 164M | Net cash position 2025 * | 269M | EV / Sales 2025 * | - |
P/E ratio 2024 * |
-2.19
x | P/E ratio 2025 * |
-1.81
x | Employees | 52 |
Yield 2024 * |
-
| Yield 2025 * |
-
| Free-Float | 88.76% |
Latest transcript on Acumen Pharmaceuticals, Inc.
1 day | +5.22% | ||
1 week | -10.88% | ||
Current month | -10.88% | ||
1 month | -22.02% | ||
3 months | -40.05% | ||
6 months | -6.76% | ||
Current year | -31.77% |
Managers | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Jim Doherty
PSD | President | 56 | Jan. 31 |
Matthew Zuga
DFI | Director of Finance/CFO | 58 | 21-04-30 |
Members of the board | Title | Age | Since |
---|---|---|---|
Daniel O'Connell
CEO | Chief Executive Officer | 54 | 06-03-31 |
Director/Board Member | 56 | 22-03-31 | |
Jeffrey Ives
BRD | Director/Board Member | 73 | 14-04-30 |
Name | Weight | AuM | 1st Jan change | Investor Rating |
---|---|---|---|---|
0.03% | 0 M€ | 0.00% | - | |
0.01% | 0 M€ | 0.00% | - |
Date | Price | Change | Volume |
---|---|---|---|
24-06-07 | 2.62 | +5.22% | 497,854 |
24-06-06 | 2.49 | -3.49% | 607,721 |
24-06-05 | 2.58 | -5.49% | 560,746 |
24-06-04 | 2.73 | -0.73% | 324,004 |
24-06-03 | 2.75 | -6.46% | 335,602 |
Delayed Quote Nasdaq, June 07, 2024 at 04:00 pm EDT
More quotesEPS Revisions
1st Jan change | Capi. | |
---|---|---|
-31.77% | 157M | |
+51.85% | 57.87B | |
+41.42% | 40.25B | |
-5.25% | 39.94B | |
-5.16% | 28.54B | |
+12.79% | 26.4B | |
-20.18% | 19.33B | |
+30.88% | 12.4B | |
+0.61% | 12.23B | |
+25.06% | 12.2B |
- Stock Market
- Equities
- ABOS Stock